IL205680A0 - Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders - Google Patents

Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders

Info

Publication number
IL205680A0
IL205680A0 IL205680A IL20568010A IL205680A0 IL 205680 A0 IL205680 A0 IL 205680A0 IL 205680 A IL205680 A IL 205680A IL 20568010 A IL20568010 A IL 20568010A IL 205680 A0 IL205680 A0 IL 205680A0
Authority
IL
Israel
Prior art keywords
antipsychotics
combinations
treatment
psychotic disorders
pde4 inhibitors
Prior art date
Application number
IL205680A
Original Assignee
Memory Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memory Pharm Corp filed Critical Memory Pharm Corp
Publication of IL205680A0 publication Critical patent/IL205680A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL205680A 2007-11-20 2010-05-11 Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders IL205680A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98922107P 2007-11-20 2007-11-20
PCT/US2008/084207 WO2009067607A2 (en) 2007-11-20 2008-11-20 Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders

Publications (1)

Publication Number Publication Date
IL205680A0 true IL205680A0 (en) 2010-11-30

Family

ID=40668089

Family Applications (1)

Application Number Title Priority Date Filing Date
IL205680A IL205680A0 (en) 2007-11-20 2010-05-11 Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders

Country Status (2)

Country Link
IL (1) IL205680A0 (en)
WO (1) WO2009067607A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493464B2 (en) 2012-02-29 2016-11-15 The Scripps Research Institute Wee1 degradation inhibitors
WO2015002915A1 (en) 2013-07-02 2015-01-08 Bristol-Myers Squibb Company Tricyclic pyri do-carboxam i d e derivatives as rock inhibitors
WO2015002926A1 (en) 2013-07-02 2015-01-08 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
CN107567452B (en) * 2015-04-29 2020-07-07 詹森药业有限公司 Imidazopiperazines and pyrazolopyrimidines and their use as AMPA receptor modulators
KR20240017991A (en) 2015-04-29 2024-02-08 라포 테라퓨틱스, 인크. Azabenzimidazoles and their use as ampa receptor modulators
JOP20190126A1 (en) * 2016-12-22 2019-05-28 H Lundbeck As Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6699890B2 (en) * 2000-12-22 2004-03-02 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
KR100951218B1 (en) * 2001-10-16 2010-04-05 메모리 파마슈티칼스 코포레이션 4-4-Alkoxy-3-Hydroxyphenyl-2-Pyrrolidone Derivatives as PDE-4 Inhibitors for the Treatment of Neurological Syndromes
WO2004010932A2 (en) * 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
CA2506297A1 (en) * 2002-11-19 2004-06-03 Memory Pharmaceuticals Corporation Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors

Also Published As

Publication number Publication date
WO2009067607A3 (en) 2009-08-13
WO2009067607A2 (en) 2009-05-28

Similar Documents

Publication Publication Date Title
IL258730A (en) Compositions and methods for treatment of microbial disorders
EP1981526A4 (en) Adiponectin for treatment of various disorders
HRP20181608T1 (en) Use of pde7 inhibitors for the treatment of movement disorders
IL201650A0 (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
HK1139036A1 (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
ZA201100482B (en) Pyrazolopyrimidines and their use for the treatment of cns disorders
EP2139475A4 (en) The use of pde7 inhibitors for the treatment of movement disorders
IL195906A0 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
PL1890684T3 (en) Treatment of sleep-wake disorders
HK1185063A1 (en) Therapeutic piperazines as pde4 inhibitors
IL190201A0 (en) Pde inhibitors and combinations thereof for the treatment of urological disorders
IL193747A0 (en) New therapeutic combinations for the treatment of depression
WO2009063492A9 (en) Novel agents for treatment of ailments and dysfunctions
IL205883A0 (en) Substittued benzoazole pde4 inhibitors for treating pulmonary and cardiovasculard disorders
ZA200806455B (en) Use of 2-imidazoles for the treatment of CNS disorders
IL205680A0 (en) Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders
EP2077838A4 (en) Methods for the treatment of a related disorders and compositions therefor
IL192877A0 (en) Use of 2-imidazoles for the treatment of cns disorders
EP2456437A4 (en) Combinations of curcummoids and mtor inhibitors for the treatment of tauopathies
ZA200802668B (en) PDE inhibitors and combinations thereof for the treatment of urological disorders
PL1879609T3 (en) Use of histones for therapeutic purposes
GB0618705D0 (en) Treatment of joint disorders
GB0503833D0 (en) Treatment of incontinence
GB0619218D0 (en) Treatment of conformational disorders